版本:
中国

BRIEF-Ligand's partner Retrophin reports additional positive data from phase 2 duet study of sparsentan in focal segmental glomerulosclerosis at asn kidney week 2016

Nov 21 Ligand Pharmaceuticals Inc :

* Data shows statistically significant difference in modified partial remission; complete remission also observed

* Further analysis supports sparsentan generally safe and well-tolerated

* Press release - Ligand's partner Retrophin reports additional positive data from phase 2 duet study of sparsentan in focal segmental glomerulosclerosis at asn kidney week 2016 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐